Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0JULJK
ADC Name	GPC1-ADC-MMAF
Synonyms	GPC1 ADC Click to Show/Hide
Drug Status	Investigative
Indication	In total 3 Indication(s) Cholangiocarcinoma [ICD11:2C12] Investigative Squamous cell cancer [ICD11:2D60-2D61] Investigative Uterine cancer [ICD11:2C78] Investigative
Drug-to-Antibody Ratio	4.1
Structure
	3D MOL	2D MOL
Antibody Name	Anti-GPC1 GPC1-ADC mAb		Antibody Info
Antigen Name	Glypican-1 (GPC1)		Antigen Info
Payload Name	Monomethyl auristatin F		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Mc-Val-Cit-PABC		Linker Info
Conjugate Type	VcMMAF was conjugated to cysteine residues on purified mAb after DTT reduction.
Combination Type	VcMMAF

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 69.7	%	BxPC-3 cells	Pancreatic ductal adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 69.70% (Day 28)	High GPC1 expression (GPC1+++)
Method Description	The SCID mice were subcutaneously inoculated with BxPC-3-GPC1-KO-Luc#15 cells and then intravenously treated with PBS, 10-mg/kg control-ADC, or 10-mg/kg humanized GPC1-ADC(MMAE) twice a week for a total of four times.
In Vivo Model	BxPC-3 CDX model
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

References

Ref 1	A glypican-1-targeted antibody-drug conjugate exhibits potent tumorgrowth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma. Neoplasia. 2021 Sep;23(9):939-950.